Impact of Covid-19 pandemic on trajectories of patients with severe alcohol use disorder treated with disulfiram.

Publication date: Feb 17, 2025

The manifestations and progression of alcohol use disorder (AUD) are influenced by a number of contextual factors, with the current coronavirus pandemic being a significant example. This pandemic has profoundly impacted nearly all aspects of human life and has, therefore, strongly influenced patients suffering from AUD. In some cases, the pandemic has led to a reduction in severity, while in others, it has had the opposite effect. In our own work we have been investigating the negative impact of the pandemic on 45 patients with AUD who were undergoing outpatient treatment, including supervised use of disulfiram (Antabuse), in a close-knit program. A linear trend analysis demonstrated significant alterations in the retention rate over a 3-year period, encompassing the pre-pandemic, pandemic, and post-pandemic periods. During the pandemic the number of treatment cancellations virtually increased. Following the pandemic, a tendency towards the normalization of patient numbers was observed. Our data indicate a high level of vulnerability among patients with severe AUD and highlight a need for the development of alternative, possibly telemedical, treatment methods.

Open Access PDF

Concepts Keywords
Alcohol Alcohol use disorder
Coronavirus Antabuse
Covid Disulfiram
Outpatient Environmental risk factor
Severe Linear trend analysis
Pandemic

Semantics

Type Source Name
disease MESH Covid-19 pandemic
disease MESH alcohol use disorder
drug DRUGBANK Disulfiram
drug DRUGBANK Ethanol
disease MESH infection
disease MESH coronavirus infections
disease IDO production
disease IDO susceptibility
disease MESH depressive symptoms
drug DRUGBANK Coenzyme M
disease IDO history
disease MESH marital status
disease MESH affective disorders
disease MESH somatoform disorders
disease MESH schizophrenia
disease MESH delusional disorders
drug DRUGBANK Naltrexone
drug DRUGBANK Acamprosate
drug DRUGBANK Nalmefene
drug DRUGBANK Baclofen
drug DRUGBANK Nicotine
disease MESH Psychotic disorders
disease MESH Personality Disorders
disease MESH ADHD
drug DRUGBANK Tropicamide
disease MESH uncertainty
disease MESH anxiety
disease MESH causality
disease MESH death
drug DRUGBANK Spinosad
disease MESH drug abuse
pathway REACTOME Reproduction

Original Article

(Visited 3 times, 1 visits today)